The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.
18 to 80 years of age;
Diagnosis of anterior circulation acute ischemic stroke;
Within 48 hours of symptoms onset;
modified Rankin Scale (mRS) score≤1 before this event;
Patients who have already or are going to receive intravenous thrombolytic/mechanical thrombectomy therapy after onset;
Patients with severe consciousness disorder, NIHSS 1a consciousness level score≥2;
Patients with limited limb mobility such as fractures and claudication upon admission;
Patients who have already or are going to receive Edaravone injection, Edaravone and DeKanol concentrated solution for injection, Butylphthalide and sodium chloride injection or Butylphthalide soft capsules after onset;
Beijing Tsinghua Chang Gung Hospital
Lead sponsor
Peking University People's Hospital
Collaborator